Novavax (NVAX) Insider Charles Newton Buys 21,270 Shares
Insider Charles Newton purchased 21,270 shares of Novavax on June 18, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Charles Newton bought 21,270 shares of Novavax, Inc. ($NVAX) on June 18, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $NVAX is down 6.2% after 1 week, down 13.7% after 1 month and up 23.3% to date (from the $9.13 close on Jun 18, 2026).
NVAX
Novavax, Inc.
Key Points
- Insider Charles Newton bought 21,270 shares of Novavax, Inc. (NVAX) on June 18, 2026, with the stock trading at $9.07.
- Novavax, Inc. has a market cap of $1.48 billion and a 52-week range of $6.13 to $11.97.
- Analysts from HC Wainwright & Co. and BTIG maintain a buy rating, with price targets of $16.00 and $19.00, respectively.
Get $NVAX trade alerts by text
We text you when insiders, Congress or big funds trade $NVAX. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Novavax, Inc. alert may contain errors. Disclosures
Charles Newton, an insider at Novavax, Inc. (NasdaqGS: NVAX), bought 21,270 shares of the company on June 18, 2026. The transaction did not occur under a prearranged trading plan. Shares of Novavax traded at $9.07 on Wednesday.
Insider Buying and Selling at Novavax, Inc.
In addition to Charles Newton's purchase, several other insiders were active around the same time. On June 20, 2026, insiders Margaret McGlynn, David Mott, Rachel King, and Richard Douglas each bought 18,880 shares. These transactions were not planned under Rule 10b5-1 plans.
Other Institutional Activity in Novavax
Shah Capital Management increased its holdings by 286,317 shares, bringing its total to 14,845,097 shares, valued at roughly $120.8 million. BlackRock, Inc. slightly reduced its position by 57,230 shares, holding 12,844,319 shares worth about $104.6 million. State Street Corp cut its stake by 553,128 shares, ending with 8,970,518 shares valued at $73 million. D. E. Shaw & Co., Inc. significantly boosted its holdings by 1,717,060 shares, reaching 7,709,858 shares worth approximately $62.8 million. Vanguard Portfolio Management LLC and Vanguard Capital Management LLC both opened new positions with 7,151,625 and 7,130,147 shares, respectively.
Novavax, Inc. Stock Down 10.2%
As of Wednesday, Novavax, Inc. traded at $9.07 per share. The biotechnology company, with a market cap of $1.48 billion, focuses on vaccine development. The stock's 52-week range is between $6.13 and $11.97. It has a 50-day moving average of $9.05 and a 200-day moving average of $8.47. Novavax's current ratio stands at 2.48, and its quick ratio is 2.38. The stock has a beta of 2.414, indicating higher volatility compared to the market.
Analysts Set New Price Targets
On May 6, 2026, TD Cowen maintained a hold rating with a $9.00 price target on Novavax. Meanwhile, HC Wainwright & Co. reaffirmed its buy rating with a $16.00 target on February 27, 2026. BTIG reiterated its buy stance with a $19.00 target on January 20, 2026. Overall, the consensus among nine analysts is a buy, with an average target price of $14.11.
About Novavax, Inc.
Novavax, Inc. is a biotechnology firm based in Gaithersburg, Maryland. It specializes in creating vaccines to tackle serious infectious diseases. The company is known for Nuvaxovid, a COVID-19 vaccine, and the R21 Matrix-M adjuvant malaria vaccine. Novavax collaborates with major pharmaceutical firms like Sanofi and Pfizer to manufacture and distribute its vaccines. Led by CEO John Charles Jacobs, the company employs 749 people.
Bottom Line
Charles Newton's recent purchase of Novavax shares highlights ongoing insider interest in the company. Novavax remains a significant player in the biotechnology sector, focusing on vaccines for infectious diseases. With a volatile stock and varying analyst opinions, investors continue to watch the company's developments closely.
Related Filing Alerts
Source: Charles Newton's Form 4 filing on $NVAX (Jun 18, 2026). Find the original filing: NVAX Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts